COMPANY PROFILE: East River BioSolutions

CED Life Science Conference 2018 - presenting at the Coulter Investment Forum

www.EastRiverBio.com
Sub-sector: Research Tools / Cell Culture
Year Founded: 2016

COMPANY PROFILE
East River BioSolutions  is revolutionizing the $7B+ cell culture market with its first-in-class tissue-specific biomaterials, enabling faster, more accurate and actionable results for scientists working in pharmaceutical development, cell biology research and regenerative medicine. Rather than isolated components or synthetic materials, the Company’s innovative patent-pending products provide a natural, physiological cell culture environment in which to develop, test and deliver treatments and cures to patients more quickly and less expensively. The company began commercializing its products in Q1 2017 to meet the growing demand for natural cell substrates, and is raising $3M to scale and reach profitability within 24 months.

FOUNDERS/MANAGEMENT TEAM
Andrea Nye, CEO
John O’Neill, CSO
Tanya Yankelevich, Director of Business Development

KEY MILESTONES TO DATE

  • Funding: $1.5M seed, June 2016
  • Launched beta product line in January 2017
  • Existing proof-of-concept revenue line
  • Accolade: Participated in Columbia-Coulter Translational Research Partnership; Choosen for highly selective inaugural membership cohort in Alexandria Center for Life Sciences LaunchLabs

POWERED BY
Columbia-Coulter Translational Research Partnership; Alexandria Center for Life Sciences LaunchLabs

CONTACT
Andrea Nye
andrea@eastriverbio.com
New York, NY

Learn more about the CED Life Science Conference.